MAP Pharmaceuticals competitors

Mr. Gerard J. Michel has served as our Chief Financial Officer, Vice President of Corporate Development and Treasurer, since November 2007. Prior to joining Biodel, Mr. Michel served in various roles at NPS Pharmaceuticals, most recently as its Chief Financial Officer and Vice President of Corporate Strategy. Previously, Mr. Michel was a principal with the consulting firm of Booz-Allen & Hamilton where he evaluated and solved strategic and operational issues for healthcare clients. Mr. Michel also served in marketing, sales, and corporate development positions, both domestic and international with Lederle Labs. Mr. Michel received an M.S. in microbiology and an M.B.A., both from the University of Rochester.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Experienced MedTech Executive with 25+ years of experience including roles as a senior executive, CEO (public and private companies), Founder/entrepreneur, Venture Capitalist and Board Member/Executive Chairman/Chairman. Served as Chairman, President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) from April of 2012 until the Company's acquisition by Allergan for $2.5B in April of 2017. Initially, I joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Currently, I am a Managing Director at RWI Ventures, serve as Chairman of the Board for ULab, HintMD and Arrinex and am a board member at Glaukos (GKOS) and Revance (RVNC). Prior to this, I served on the boards of several private companies, held operating roles in large, public companies and venture-backed start-ups including US Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where I was the founder and CEO. I received my B.A. from the University of Notre Dame (1987) and am a named inventor on 17 patent applications.

John Kollins is a President/CEO/Co-Founder at SATSUMA PHARMACEUTICALS INC, Board Member at SATSUMA PHARMACEUTICALS INC, and Advisor at Covx and is based in South San Francisco, California. He has experience at ATHENA NEUROSCIENCES INC and Elan Pharmaceutical and has worked as Chief Operating Officer at Oxigene Inc, Vice President at SurroMed, and Advisor To CEO at SurroMed. John works or has worked as Consultant at Covx, CHAIRMAN at CovX Research LLC, and Consultant at Entelos. He studied at Duke University between 1981 and 1985 and University of Virginia Darden School of Business between 1987 and 1989.

Cedric Francois' primary areas of expertise are immunology and immune system mediated disease. Cedric Francois received his medical degree from the University of Leuven in Belgium and his Ph.D. in Physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois joined the research team that performed the first successful hand transplantation and the Louisville Face Transplant Team, whose work supported the first human face transplantation in Lyon, France in 2005. He has published numerous publications and is the principal author on the clinical report of the first four human hand transplantations. He is an inventor on many biotechnology patent applications, including all of Potentia and Apellis' proprietary patent applications. Dr. Francois led Potentia to become the first group to test complement-inhibiting drug candidates for age-related macular degeneration, now an established mechanism in that disease. In October 2009 Alcon, the world's largest ophthalmology company, entered into a licensing and option to purchase agreement with Potentia Pharmaceuticals and took over all of its operations. He is currently President and CEO of Apellis Pharmaceuticals